Anti-angiogenic drugs for second-line treatment of NSCLC patients: just new pawns on the chessboard?
暂无分享,去创建一个
[1] C. Lequaglie,et al. What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. , 2015, Critical reviews in oncology/hematology.
[2] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[3] Andreas Sashegyi,et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial , 2014, The Lancet.
[4] Ning Li,et al. Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer , 2014, PloS one.
[5] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[6] P. V. Van Schil,et al. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it. , 2014, Translational lung cancer research.
[7] Patrick Pauwels,et al. Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. , 2014, Critical reviews in oncology/hematology.
[8] R. Kaiser,et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. , 2014, The Lancet. Oncology.
[9] C. Pallarés,et al. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents , 2013, Clinical and Translational Oncology.
[10] J. Schiller,et al. Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] C. Gridelli,et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] R. Kaiser,et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] R. Kaiser,et al. Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.
[14] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[15] Miklos Pless,et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.